Mirati Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012
Total Revenue - -
Cost of Revenue - -
Gross Profit - -
Operating Expenses
Research and Development 19,797 15,081
Sales, General and Admin. 11,144 5,394
Non-Recurring Items 1,025 -
Other - -
Operating Income (31,966) (20,475)
Income From Continuing Operations
Add'l Income/Expense Items (20,916) 228
Earnings Before Interest and Tax (52,882) (20,247)
Interest Expense - -
Earnings Before Tax (52,882) (20,247)
Income Tax (23) 39
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (52,859) (20,286)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (52,859) (20,286)
Preferred Stock and Other Adjustments - -
Net Income Applicable to Common Shareholders (52,859) (20,286)